1. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Issue 14 (5th April 2019) Authors: Voss, Martin H.; Bhatt, Rupal S.; Vogelzang, Nicholas J.; Fishman, Mayer; Alter, Robert S.; Rini, Brian I.; Beck, J. Thaddeus; Joshi, Monika; Hauke, Ralph; Atkins, Michael B.; Burgess, Earle; Logan, Theodore F.; Shaffer, David; Parikh, Rahul; Moazzam, Nauman; Zhang, Xiaosha; Glasser, Chad; Sherma... Journal: Cancer Issue: Volume 125:Issue 14(2019) Page Start: 2400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗